CAPR Capricor Therapeutics Inc.

1.29
-0.13  -9%
Previous Close 1.42
Open 1.39
Price To Book 0.98
Market Cap 6,743,343
Shares 5,227,398
Volume 1,165,850
Short Ratio
Av. Daily Volume 662,470
Stock charts supplied by TradingView

NewsSee all news

  1. Capricor Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

    -To Report Final 12-month HOPE-2 Data in the Second Quarter- -Exosomes Platform Technology Expanded to Potentially Combat the Novel Coronavirus- -To Host Conference Call and Webcast Today at 4:30 p.m. ET- LOS ANGELES,

  2. Capricor Therapeutics Announces Strategic Plan for Exosome Platform Technology Products Expansion

    LOS ANGELES, March 17, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of

  3. Capricor Therapeutics to Present Fourth Quarter and Full Year 2019 Financial Results and Recent Corporate Update on March 18

    LOS ANGELES, March 11, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of

  4. Capricor Therapeutics Announces Closing of $5.1 Million Offering Priced At-the-Market

    LOS ANGELES, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ:CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of

  5. Capricor Therapeutics Announces Pricing of $5.1 Million Offering Priced At-the-Market

    LOS ANGELES, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ:CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 12-month data due 2Q 2020.
CAP-1002 HOPE-2
Duchenne Muscular Dystrophy (DMD)
Phase 2 data released May 12, 2017 - primary endpoint unlikely to be met.
CAP-1002 ALLSTAR
Myocardial infarction (heart attack)
Phase 2 completed. Waiting on data from additional study to determine future
Cenderitide
Ambulatory heart failure

Latest News

  1. Capricor Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

    -To Report Final 12-month HOPE-2 Data in the Second Quarter- -Exosomes Platform Technology Expanded to Potentially Combat the Novel Coronavirus- -To Host Conference Call and Webcast Today at 4:30 p.m. ET- LOS ANGELES,

  2. Capricor Therapeutics Announces Strategic Plan for Exosome Platform Technology Products Expansion

    LOS ANGELES, March 17, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of

  3. Capricor Therapeutics to Present Fourth Quarter and Full Year 2019 Financial Results and Recent Corporate Update on March 18

    LOS ANGELES, March 11, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of

  4. Capricor Therapeutics Announces Closing of $5.1 Million Offering Priced At-the-Market

    LOS ANGELES, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ:CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of

  5. Capricor Therapeutics Announces Pricing of $5.1 Million Offering Priced At-the-Market

    LOS ANGELES, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ:CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of

  6. Capricor Therapeutics Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Update

    Provides Update on End of Phase Type-B Meeting with FDA Positive Data from the HOPE-2 Clinical Trial Presented at World Muscle Society To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS

  7. Capricor Therapeutics to Present Third Quarter 2019 Financial Results and Recent Corporate Update on November 7

    LOS ANGELES, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of

  8. Capricor Therapeutics to Host Key Opinion Leader Call on the Role of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy (DMD)

    Call Scheduled for Thursday, October 24th at 10:30am Eastern Time LOS ANGELES, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a clinical-stage biotechnology company focused on the development

  9. Capricor Presents Additional Positive Data from Ongoing HOPE-2 Study of CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society: Data Demonstrates Improved PUL 2.0 Performance at 6 Months

    --Company Exploring Potential for Accelerated Approval under RMAT Designation, an Expedited Program for Regenerative Therapies-- --Company to Host Conference Call Today at 5:30 AM PT / 8:30 AM ET-- LOS ANGELES, Oct.

  10. Capricor to Present Interim Results from the HOPE-2 Trial in a Late Breaking Session of the World Muscle Society and Company to Host Conference Call Monday, October 7 at 5:30 AM PT / 8:30 AM ET

    LOS ANGELES, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of

  11. Capricor Therapeutics to Meet with FDA to Discuss CAP-1002 to Treat Duchenne Muscular Dystrophy

    LOS ANGELES, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of

  12. Capricor Therapeutics to Present Results from the HOPE-2 Trial of CAP-1002 in Duchenne Muscular Dystrophy in a Late Breaking Session of the World Muscle Society

    LOS ANGELES, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of

  13. Capricor Therapeutics to Present at Upcoming Conferences

    LOS ANGELES, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR),  a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of